BlossomHill Therapeutics Files for $100M Nasdaq IPO to Advance Macrocyclic Cancer Pipeline
Key Insights
BlossomHill Therapeutics (search), a clinical-stage oncology biotech, filed for a $100 million Nasdaq IPO under the ticker "BLSM" on July 16, 2026.
The company's lead asset BH-30643 is an oral macrocyclic OMNI-EGFR (search) inhibitor in a global Phase 1/2 trial targeting EGFR-mutant NSCLC, including patients with the C797S resistance mutation.
A second program, BH-30236, is a macrocyclic CLK (search) inhibitor in Phase 1 for relapsed/refractory AML and higher-risk MDS, with FDA Orphan Drug Designation already granted.
BlossomHill Therapeutics (search), a San Diego-based clinical-stage oncology company, filed for an initial public offering on the Nasdaq Global Select Market on July 16, 2026, seeking to raise $100 million to advance its pipeline of macrocyclic small-molecule cancer therapies. The company plans to list under the proposed ticker "BLSM," with J.P. Morgan, Leerink Partners, Guggenheim Securities, LifeSci Capital, and H.C. Wainwright & Co. serving as joint bookrunners on the all-primary offering.
Founded in 2020, BlossomHill brings a distinctive macrocyclic approach to cancer drug design, creating large ring-shaped molecules that form tighter bonds with disease-driving proteins than conventional cancer therapies. The company is led by scientific founder Dr. J. Jean Cui, the lead inventor of three FDA-approved targeted therapies: Xalkori, Lorbrena, and Augtyro. Cui was elected to the National Academy of Engineering in 2024.
Pipeline Targets Major Resistance Gaps
BlossomHill's lead program, BH-30643, is an oral, non-covalent, macrocyclic OMNI-EGFR (search) inhibitor currently in a global Phase 1/2 trial called SOLARA. The study is enrolling patients with EGFR-mutant non-small cell lung cancer (search) (NSCLC), including those harboring the common C797S resistance mutation as well as patients who are TKI-naive. The trial spans over 40 sites across 10 countries, including the United States, Australia, Canada, Japan, South Korea, and several other Asia-Pacific nations.
The second clinical-stage asset, BH-30236, is a macrocyclic CLK (search) inhibitor in Phase 1 development for relapsed or refractory acute myeloid leukemia (search) (AML) and higher-risk myelodysplastic syndromes (search) (HR-MDS). The program is evaluating both monotherapy and combination with venetoclax, aiming to address aberrant alternative splicing and overcome venetoclax resistance. The FDA has granted Orphan Drug Designation to BH-30236 for AML.
A preclinical candidate, BH-501284 (search), rounds out the disclosed pipeline. This non-covalent, Switch-II pocket pan-KRAS (search) inhibitor is designed to deliver durable, selective KRAS inhibition while sparing HRAS and NRAS.
Financial Position and Use of Proceeds
BlossomHill remains a pre-revenue company, reporting operating expenses of $64.0 million and a net loss of $60.6 million for 2025. The company has raised over $257 million from private placements since inception, including an $84 million Series B round in December led by Cormorant Asset Management, Janus Henderson, OrbiMed, and other life science-focused investors. As of March 31, 2026, the company held approximately $116 million in cash.
IPO proceeds are earmarked to advance BH-30643 through its global Phase 1/2 trial and into a planned Phase 2 study in EGFR (search)-mutant NSCLC, progress BH-30236 in AML/HR-MDS through ongoing Phase 1 monotherapy and venetoclax combination cohorts, and complete IND-enabling studies for BH-501284 (search) followed by an IND filing and Phase 1 initiation. Remaining funds will support R&D, capital expenditures, working capital, and general corporate purposes.
Market Context and Competitive Landscape
The worldwide EGFR (search) therapeutics market was valued at approximately $8.0 billion in 2025 and is projected to exceed $13.4 billion by 2030, driven by expanding precision oncology adoption and earlier-line combination strategies. BlossomHill's pipeline targets significant resistance gaps, including EGFR C797S mutations in NSCLC and venetoclax-resistant AML.
Key competitors in the space include AstraZeneca with osimertinib, Johnson & Johnson with amivantamab, and a range of companies developing therapies against specific mutations, including Astellas, Servier, Bristol Myers Squibb, Syndax, Kura, and Revolution Medicines in the pan-RAS arena.
BlossomHill's intellectual property estate comprises 29 patent families, 10 pending U.S. non-provisionals, 11 PCT applications, and 265 pending foreign applications. The company employs 63 full-time staff and operates from approximately 46,300 square feet of office and laboratory space in San Diego under a lease extending through 2035.